← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2002First marketed drug
Jan 22, 2010First NDA
Jan 22, 2010Last known activity
Mar 5, 2019
Defunct as of Jul 10, 2024
Timeline
1990s
- Jan 1, 1995
Acorda Therapeutics— Founded
2010s
- Jan 22, 2010
dalfampridine— NDA Organization
- Dec 21, 2012
Neuronex, Inc.— Acquired
- Oct 22, 2014
Civitas Therapeutics— Acquired
- Jan 19, 2016
Biotie Therapies— Acquired
- Dec 21, 2018
levodopa— NDA Secondary Org
2020s
- Jul 10, 2024
Acorda Therapeutics— Defunct
Drugs by trial phase (25 distinct, 66 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (0 own, 2 via acquisition)
Phase 2 (4 own, 10 via acquisition)
Phase 1 (6 own, 2 via acquisition)
Indications
Approved for
Studied for
- Asthma
- Cerebral Infarction
- Cerebral Palsy
- Drug Resistant Epilepsy
- Epilepsy
- Fatigue
- Heart Failure
- Hepatic Insufficiency
- Ischemia
- Liver Failure
- Migraine Disorders
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Muscle Spasticity
- Myelitis
- Myelitis, Transverse
- Neuritis
- Neuromyelitis Optica
- Optic Nerve Diseases
- Optic Neuritis
- Optic Neuropathy, Ischemic
- Parkinson Disease
- Renal Insufficiency
- Respiratory Aspiration
- Sclerosis
- Seizures
- Spinal Cord Injuries
- Stroke
- Ventricular Dysfunction
- Ventricular Dysfunction, Left
- Wounds and Injuries
Marketed drugs (2)
Subsidiaries (3 direct, 7 total across the full acquisition tree)
Recent trials (50)
- NCT03887884Study directorPhase 1Mar 5, 2019
- NCT03887884Lead sponsorPhase 1Mar 5, 2019
- NCT03200080CollaboratorPhase 1Sep 18, 2017
- NCT03212313CollaboratorPhase 1Jun 30, 2017
- NCT03051607CollaboratorPhase 3Apr 30, 2017
- NCT02905227Lead sponsorPhase 1Sep 1, 2016
- NCT02905227Study directorPhase 1Sep 1, 2016
- NCT02807675Lead sponsorPhase 1Jun 1, 2016
- NCT02812394Lead sponsorPhase 1Jun 1, 2016
- NCT02812394Study directorPhase 1Jun 1, 2016
- NCT02807675Study directorPhase 1Jun 1, 2016
- NCT02663999Study directorPhase 1Jan 1, 2016
- NCT02663999Lead sponsorPhase 1Jan 1, 2016
- NCT02633839Study directorPhase 1Dec 1, 2015
- NCT02633007Study directorPhase 1Dec 1, 2015
Details
- Founded
- Ardsley, NY, US Jan 1, 1995
- First NDA
- Jan 22, 2010
- Last known activity
- Mar 5, 2019
Designations held
- Orphan drug
- Priority review